Funded Biomarker Testing
3 items
Promoter Methylation testing should be performed for all MMR cases with abnormal MLH1 results*.
Funded Biomarker Disease Site: Adrenal Gland, Bladder/ Urothelial, Colorectal, Endometrium, Esophagus, Hepatobiliary, Ocular, Ovary, Pancreas, Skin, Small Bowel, Stomach
Biomarker: MLH1 Methylation
Testing Method:Methylation
Testing Site: Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, Trillium Health Partners, University Health Network
Reflex testing on newly diagnosed tumours with invasive biliary/gallbladder adenocarcinoma.
Funded Biomarker Disease Site: Hepatobiliary
Biomarker: MLH1, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Testing on previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) where FGFR2 directed therapy is being considered
Funded Biomarker Disease Site: Hepatobiliary
Biomarker: FGFR2
Testing Method:Sequencing
Testing Site: Hamilton Health Sciences, Hospital for Sick Children (SickKids), London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System